GEA Group Aktiengesellschaft (ETR:G1A) reported higher second-quarter order intake, sales and profitability, prompting the company to raise its full-year 2026 guidance and announce a new share buyback program of up to EUR 500 million.

Chief Executive Officer Stefan Klebert said the company’s Executive Board approved the buyback, which will be conducted in two tranches through the end of 2027. The first tranche, worth up to EUR 250 million, was scheduled to begin the day after the earnings call and run for seven months. Repurchased shares will be canceled upon completion of the program.

The new authorization follows EUR 700 million in share repurchases and cancellations completed over the previous five years, bringing GEA’s planned cumulative buyback volume between 2021 and 2027 to EUR 1.2 billion. Klebert said the program would not limit investments, research and development spending, or potential acquisitions. GEA also plans to donate part of the program’s guaranteed outperformance, estimated at roughly EUR 250,000, to the Deutsche Universitätsstiftung to support talented students in STEAM education.

Order intake increased 14.2% year over year to EUR 1.5 billion, while organic order intake growth was 15.4%, according to Chief Financial Officer Alexander Kocherscheidt. Growth was broad-based across order sizes, with base orders making the largest absolute contribution. The company also booked EUR 34 million in large orders above EUR 15 million, compared with no large orders in the prior-year quarter.

Sales rose 10% to EUR 1.4 billion, or 11% organically. New-machine sales increased organically by 11.6%, while service revenue rose 10.2%. Kocherscheidt said this represented the 23rd consecutive quarter of organic growth in service sales. Service accounted for 39.6% of sales, down 0.5 percentage points from a year earlier as new-machine sales grew slightly faster.

EBITDA before restructuring expenses increased 15.6% to EUR 251 million, and the related margin rose 0.9 percentage points to a record 17.4%. The company attributed the improvement primarily to higher volumes and improved gross margin. Return on capital employed also reached a record 36.8%.

GEA’s net liquidity improved to a net cash position of EUR 71 million at the end of the second quarter, compared with a net debt position at the end of the second quarter of 2025. Free cash flow was EUR 151 million in the quarter, supported by operating cash flow of EUR 185 million and relatively low capital expenditure of EUR 39 million. The company said it expects capital expenditures to increase during the second half and continues to expect full-year free cash flow at roughly the same level as in 2025.

• Pure Flow Processing: Organic order intake rose 9.8% and organic sales increased 12.9%. EBITDA before restructuring expenses rose EUR 13 million to EUR 145 million, although the margin declined 0.5 percentage points to 27.5% amid higher selling expenses tied to order intake development.
• Nutrition Plant Engineering: Organic order intake rose more than 40%, aided by two dairy-processing large orders totaling EUR 34 million. Organic sales increased 10.6%, while EBITDA before restructuring expenses rose to EUR 56 million from EUR 45 million. The margin expanded 1.3 percentage points to 11.3%.
• Pharma & Food Applications: Organic order intake declined 9.6%, which management attributed to order timing, though base orders grew more than 6%. Organic sales rose 8.5%. EBITDA before restructuring expenses climbed 30% to EUR 45 million, and the margin reached a quarterly record of 16.2%.
• Farm Technologies: Organic order intake grew 11.4% and organic sales increased 15.4%, led by a 22.6% rise in new-machine sales. EBITDA before restructuring expenses increased EUR 3 million to EUR 30 million, while the margin edged down 0.2 percentage points to 14.2% due to mix effects and a lower service-sales share.

Management said dairy processing and dairy farming remained strong sources of demand, while food, pharma and other industries also contributed. Klebert highlighted demand related to high-protein products and said the company sees a promising pipeline for larger Nutrition Plant Engineering projects. He added that GEA does not currently expect a significant contribution from data-center-related business.

Based on its first-half performance and expectations for the remainder of the year, GEA raised its full-year outlook. The company now expects:

• Organic sales growth of 6% to 8%, compared with prior guidance of 5% to 7%.
• EBITDA margin before restructuring expenses of 17.0% to 17.4%, compared with prior guidance of 16.6% to 17.2%.
• Return on capital employed of 36% to 40%, compared with prior guidance of 34% to 38%.

Klebert said the revised margin range brings the company close to the lower end of its Mission 30 target of a 17% to 19% margin, though this year’s guidance excludes restructuring expenses while the company plans to report EBITDA on an all-in basis beginning in 2027. He said GEA does not expect a significant margin decline from the reporting change, as its transformation work is expected to be largely completed by the end of 2026.

Management said the company remains confident in full-year delivery but cautioned that comparisons become more demanding in the second half, particularly against a strong fourth quarter in the prior year. Klebert said order intake is expected to show meaningful growth for the full year, supported by a solid base-order level and a pipeline of potential larger projects.

GEA Group Aktiengesellschaft engages in the development and production of systems and components to the food, beverage, and pharmaceutical industries. It operates through Separation & Flow Technologies, Liquid & Power Technologies, Food & Health Technologies, Farm Technologies, and Heating & Refrigeration Technologies segments. The Separation & Flow Technologies segment manufacture process-related components and machinery including notably separators, decanters, homogenizers, valves, and pumps.

CECO Environmental Q2 Earnings Call Highlights

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles